Nimotuzumab is a cutting-edge monoclonal antibody therapy designed to treat various epithelial cancers, including head and neck cancer, glioma, and non-small cell lung cancer (NSCLC). Developed with advanced biotechnology, Nimotuzumab offers a targeted approach to cancer therapy, minimizing side effects while maximizing efficacy. This document explores Nimotuzumab’s mechanism, clinical outcomes, and benefits, underscoring its role...